- Home
- AKAN vs MBRX Comparison
AKAN vs MBRX Comparison
Compare AKAN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKAN | MBRX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.1M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AKAN | MBRX |
|---|---|---|
| Price | $19.10 | $2.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 505.6K | 221.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.25 |
| 52 Week High | $78.90 | $7.98 |
Technical Indicators
Market Signals| Indicator | AKAN | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 59.71 |
| Support Level | $0.91 | $2.20 |
| Resistance Level | $29.84 | $2.95 |
| Average True Range (ATR) | 2.65 | 0.20 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 54.39 | 62.30 |
Price Performance
Historical ComparisonAbout AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.